Last reviewed · How we verify
NCT02940223
Ethyl Icosapentate and Physical Activity in Treating Fatigue in Patients With Advanced Cancer
Phase 2 trial testing Ethyl Icosapentate in Advanced Malignant Neoplasm in 2 participants. Terminated before completion.
24 November 2020
Quick facts
| Lead sponsor | M.D. Anderson Cancer Center |
|---|---|
| Phase | Phase 2 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | supportive care |
| Enrollment | 2 |
| Start date | 16 March 2017 |
| Primary completion | 24 November 2020 |
| Estimated completion | 24 November 2020 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Ethyl Icosapentate — full drug profile →
- Exercise Intervention
- Exercise Intervention
- Laboratory Biomarker Analysis — full drug profile →
- Placebo
- Quality-of-Life Assessment
- Questionnaire Administration
Conditions studied
- Advanced Malignant Neoplasm — all drugs for Advanced Malignant Neoplasm →
- Fatigue — all drugs for Fatigue →
Sponsor
M.D. Anderson Cancer Center — full company profile →
Who can join
18 and older, any sex, with Advanced Malignant Neoplasm or Fatigue. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This randomized phase II trial studies how well ethyl icosapentate and physical activity work in treating fatigue in patients with cancer that has spread from where it started to other places in the body. Ethyl icosapentate and physical activity may provide more robust and clinically effective improvement of cancer related fatigue, which may facilitate patients continuing cancer therapy since it would be tolerated and effective in controlling disease.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Recent developments in the treatment of metastatic colorectal cancer.
Loree JM, Kopetz S. · · 2017 · cited 70× · PMID 28794806 · DOI 10.1177/1758834017714997
Verify or expand the search:
- PubMed search for NCT02940223
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Ethyl Icosapentate
Trials testing the same drug.
- NCT04239950 — Efficacy of Ethyl Icosapentate in Patients With Severe Hypertriglyceridemia · Phase 3 · completed
Other recruiting trials for Advanced Malignant Neoplasm
Currently open trials in the same condition.
- NCT06581419 — A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors · Phase 1, PHASE2 · recruiting
- NCT05985278 — Clinical Application of Lutetium [177Lu]-Catalase in Tumor Radionuclide Therapy · EARLY_PHASE1 · recruiting
- NCT04585750 — The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) · Phase 1, PHASE2 · recruiting
- NCT03203525 — Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurre · Phase 1 · active not recruiting
- NCT04119037 — Cordotomy in Reducing Pain in Patients With Advanced Cancer · NA · active not recruiting
Other M.D. Anderson Cancer Center trials
Trials by the same sponsor.
- NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
- NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
- NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
- NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
- NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02940223 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
- Last refreshed: 10 June 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02940223.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing